TABLE 56Mixed-treatment comparison – MMSE at 24–26 weeks (mean change from baseline; all measurement populations): input data

Evidence NetworkComparisonStudyWMD95% CI
Image ch3fu4.jpg
Donepezil vs placeboRogers et al. (1998)1131.2840.604 to 1.964
Mohs et al. (2001)1101.3500.188 to 2.512
Winblad et al. (2001)1161.4900.548 to 2.432
Gauthier et al. (2002)1052.0600.880 to 3.240
AD2000 (2004)1030.500−0.250 to 1.250
Seltzer et al. (2004)1151.2500.171 to 2.329
Mazza et al. (2006)1181.450−3.720 to 6.620
Rivastigmine vs placeboFeldman and Lane (2007)1381.2500.670 to 1.830
Winblad et al. (2007)1400.9320.461 to 1.403

From: 3, Assessment of clinical effectiveness

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.